AbbVie Quick Ratio 2010-2023 | ABBV

Historical quick ratio values for AbbVie (ABBV) over the last 10 years.
AbbVie Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2023-09-30 $29.24B $34.77B 0.84
2023-06-30 $24.80B $32.24B 0.77
2023-03-31 $22.66B $27.59B 0.82
2022-12-31 $24.88B $29.54B 0.84
2022-09-30 $27.19B $32.71B 0.83
2022-06-30 $25.70B $34.47B 0.75
2022-03-31 $23.03B $32.52B 0.71
2021-12-31 $24.80B $35.19B 0.71
2021-09-30 $25.86B $28.53B 0.91
2021-06-30 $22.61B $28.68B 0.79
2021-03-31 $23.30B $31.95B 0.73
2020-12-31 $20.86B $28.66B 0.73
2020-09-30 $19.54B $24.18B 0.81
2020-06-30 $17.20B $24.65B 0.70
2020-03-31 $49.91B $16.47B 3.03
2019-12-31 $47.71B $15.59B 3.06
2019-09-30 $18.24B $17.49B 1.04
2019-06-30 $13.21B $16.94B 0.78
2019-03-31 $12.71B $13.90B 0.91
2018-12-31 $15.34B $17.24B 0.89
2018-09-30 $16.68B $15.39B 1.08
2018-06-30 $12.27B $17.22B 0.71
2018-03-31 $18.71B $17.06B 1.10
2017-12-31 $19.62B $16.64B 1.18
2017-09-30 $17.15B $13.03B 1.32
2017-06-30 $15.38B $12.26B 1.26
2017-03-31 $14.12B $8.84B 1.60
2016-12-31 $14.74B $9.78B 1.51
2016-09-30 $14.66B $9.10B 1.61
2016-06-30 $15.04B $9.27B 1.62
2016-03-31 $14.83B $10.66B 1.39
2015-12-31 $14.60B $10.89B 1.34
2015-09-30 $16.07B $8.81B 1.82
2015-06-30 $15.25B $11.26B 1.36
2015-03-31 $14.39B $11.05B 1.30
2014-12-31 $14.96B $11.39B 1.31
2014-09-30 $16.55B $6.64B 2.49
2014-06-30 $16.75B $6.32B 2.65
2014-03-31 $16.23B $6.22B 2.61
2013-12-31 $16.70B $6.88B 2.43
2013-09-30 $15.37B $6.88B 2.24
2013-06-30 $14.58B $6.81B 2.14
2013-03-31 $13.89B $6.77B 2.05
2012-12-31 $14.26B $6.78B 2.11
2012-09-30 $9.97B $5.37B 1.86
2012-06-30 $5.13B $4.84B 1.06
2012-03-31 $5.84B $5.52B 1.06
2011-12-31 $6.48B $5.90B 1.10
2011-09-30 $0.00B 0.00
2011-06-30 $0.00B 0.00
2011-03-31 $0.00B 0.00
2010-12-31 $7.38B $3.76B 1.96
2009-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $255.244B $58.054B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $558.335B 99.35
Novo Nordisk (NVO) Denmark $447.093B 41.34
Johnson & Johnson (JNJ) United States $381.674B 15.11
Merck (MRK) United States $269.189B 34.38
Novartis AG (NVS) Switzerland $205.538B 14.28
AstraZeneca (AZN) United Kingdom $198.420B 17.78
Pfizer (PFE) United States $164.254B 10.14
Sanofi (SNY) $117.221B 10.60
Innoviva (INVA) United States $0.941B 8.49